- Home
- ARDX vs ANAB Comparison
ARDX vs ANAB Comparison
Compare ARDX & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARDX
- ANAB
- Stock Information
- Founded
- ARDX 2007
- ANAB 2005
- Country
- ARDX United States
- ANAB United States
- Employees
- ARDX N/A
- ANAB N/A
- Industry
- ARDX Biotechnology: Pharmaceutical Preparations
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ARDX Health Care
- ANAB Health Care
- Exchange
- ARDX Nasdaq
- ANAB Nasdaq
- Market Cap
- ARDX 882.9M
- ANAB 1.0B
- IPO Year
- ARDX 2014
- ANAB 2017
- Fundamental
- Price
- ARDX $5.57
- ANAB $39.71
- Analyst Decision
- ARDX Strong Buy
- ANAB Buy
- Analyst Count
- ARDX 10
- ANAB 12
- Target Price
- ARDX $10.65
- ANAB $63.30
- AVG Volume (30 Days)
- ARDX 4.4M
- ANAB 372.7K
- Earning Date
- ARDX 10-30-2025
- ANAB 11-04-2025
- Dividend Yield
- ARDX N/A
- ANAB N/A
- EPS Growth
- ARDX N/A
- ANAB N/A
- EPS
- ARDX N/A
- ANAB N/A
- Revenue
- ARDX $398,234,000.00
- ANAB $169,467,000.00
- Revenue This Year
- ARDX $18.90
- ANAB $37.52
- Revenue Next Year
- ARDX $31.52
- ANAB N/A
- P/E Ratio
- ARDX N/A
- ANAB N/A
- Revenue Growth
- ARDX 58.12
- ANAB 196.42
- 52 Week Low
- ARDX $3.21
- ANAB $12.21
- 52 Week High
- ARDX $6.78
- ANAB $40.96
- Technical
- Relative Strength Index (RSI)
- ARDX 52.45
- ANAB 75.16
- Support Level
- ARDX $5.59
- ANAB $34.22
- Resistance Level
- ARDX $6.73
- ANAB $40.96
- Average True Range (ATR)
- ARDX 0.30
- ANAB 2.20
- MACD
- ARDX 0.09
- ANAB -0.04
- Stochastic Oscillator
- ARDX 35.44
- ANAB 81.64
About ARDX Ardelyx Inc.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).